Approval · Notice of Compliance 2471 · 2001
AMERGE: Notice of Compliance 2471
Issued August 7, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2471
- Date
- August 7, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
Products in this notice
Medicinal ingredients
- NARATRIPTAN HCL 1 MG per TAB
- NARATRIPTAN HCL 2.5 MG per TAB